Bio-Path (NASDAQ:BPTH) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report published on Sunday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reiterated a buy rating and set a $20.00 price objective on shares of Bio-Path in a research report on Monday, July 8th.

Bio-Path Price Performance

Bio-Path stock opened at $0.88 on Friday. Bio-Path has a 52-week low of $0.86 and a 52-week high of $21.60. The firm’s fifty day moving average is $1.20 and its 200 day moving average is $2.19.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter in the prior year, the firm posted ($10.60) EPS. Equities research analysts expect that Bio-Path will post -6.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.